SHINE Medical Technologies has secured $150m in a Series C-5 funding round to support the marketing of its medical isotope technologies developed for diagnostic and therapeutic applications.

The funds will also be used to develop new applications by leveraging fusion-based technologies.

Koch Disruptive Technologies led the financing, which was joined by Fidelity Management & Research Company and Baillie Gifford, as well as additional new and existing investors.

Koch Disruptive Technologies president Chase Koch said: “SHINE’s innovative medical isotope technologies, which play a crucial role in identifying and treating patients with debilitating diseases, are astounding.